MUMBAI, India, March 13 -- Intellectual Property India has published a patent application (202641024817 A) filed by Vignan Institute Of Pharmaceutical Technology, Visakhapatnam, Andhra Pradesh, on March 2, for 'development of self-assembling nanogels for targeted delivery of crispr-cas9 in gene therapy applications.'
Inventor(s) include S. Satya Lakshmi; Y. Srinivasa Rao; G. Chandrasekhara Rao; U. Bhavani; and K. Srilekhya.
The application for the patent was published on March 13, under issue no. 11/2026.
According to the abstract released by the Intellectual Property India: "The present invention introduces an innovative approach to gene therapy through the development of self-assembling nanogels designed specifically for the targeted delivery of CRISPR-Cas9 complexes. These nanogels are engineered from biocompatible polymers that spontaneously form nanoscale hydrogel structures in aqueous environments, encapsulating the CRISPR-Cas9 machinery while incorporating targeting ligands for precise cellular uptake. By addressing key challenges in traditional delivery methods, such as off-target effects, low efficiency, and immune responses, this technology enhances the safety and efficacy of gene editing. The nanogels protect the CRISPR components from degradation, enable controlled release at the target site, and facilitate endosomal escape for nuclear delivery. Experimental validations demonstrate improved transfection rates in vitro and in vivo, with applications spanning genetic disorders like cystic fibrosis and muscular dystrophy. This invention represents a scalable, cost-effective platform that could revolutionize personalized medicine by making CRISPR-based therapies more accessible and reliable."
Disclaimer: Curated by HT Syndication.
